Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series
Within-class switching from a prior anti-CD20 mAb therapy to ublituximab is feasible and may improve outcomes in some people with MS.
Authors
- Jonathan Calkwood
- Joshua Katz (ORCID: https://orcid.org/0000-0002-5638-5232)
- Regina Berkovich (ORCID: https://orcid.org/0000-0001-7637-0241)
- April Erwin
- Simon Faissner (ORCID: https://orcid.org/0000-0002-3412-762X)
- Heidi Crayton (ORCID: https://orcid.org/0009-0008-6785-8155)
- Ralf Gold
- Mark Leekoff
Institutions
- Wellesley College (US)
- Multiple Sclerosis Foundation (US)
- Rocky Mountain Multiple Sclerosis Clinic (US)
- Oncotherapeutics (United States) (US)
- Hollywood Orthopaedic Group (AU)
- Multiple Sclerosis Center of Atlanta (US)
- St. Josef-Hospital (DE)
- MSD (Austria) (AT)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-04
- DOI
- https://doi.org/10.3389/fimmu.2025.1527102
- Citations
- 1
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- TG Therapeutics